Skip to main content

Omlonti FDA Approval History

Last updated by Judith Stewart, BPharm on Sep 28, 2022.

FDA Approved: Yes (First approved September 22, 2022)
Brand name: Omlonti
Generic name: omidenepag isopropyl
Dosage form: Ophthalmic Solution
Company: Santen Inc.
Treatment for: Glaucoma/Intraocular Hypertension

Omlonti (omidenepag isopropyl) is a relatively selective prostaglandin E2 (EP2) receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Development timeline for Omlonti

Sep 26, 2022Approval FDA Approves Omlonti (omidenepag isopropyl ophthalmic solution) for Reduction of Elevated Intraocular Pressure in Primary Open-Angle Glaucoma or Ocular Hypertension

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.